SG11202108399PA - Indolo heptamyl oxime analogue as parp inhibitor - Google Patents

Indolo heptamyl oxime analogue as parp inhibitor

Info

Publication number
SG11202108399PA
SG11202108399PA SG11202108399PA SG11202108399PA SG11202108399PA SG 11202108399P A SG11202108399P A SG 11202108399PA SG 11202108399P A SG11202108399P A SG 11202108399PA SG 11202108399P A SG11202108399P A SG 11202108399PA SG 11202108399P A SG11202108399P A SG 11202108399PA
Authority
SG
Singapore
Prior art keywords
heptamyl
indolo
parp inhibitor
oxime
analogue
Prior art date
Application number
SG11202108399PA
Other languages
English (en)
Inventor
Yanbin Hu
Gang Li
Fei Sun
Zhigang Chi
Jin Luo
Charles Z Ding
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11202108399PA publication Critical patent/SG11202108399PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202108399PA 2019-02-02 2020-02-03 Indolo heptamyl oxime analogue as parp inhibitor SG11202108399PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910107947 2019-02-02
CN201910111576 2019-02-12
CN201910684020 2019-07-26
PCT/CN2020/074220 WO2020156577A1 (zh) 2019-02-02 2020-02-03 用于parp抑制剂的吲哚并七元酰肟类似物

Publications (1)

Publication Number Publication Date
SG11202108399PA true SG11202108399PA (en) 2021-09-29

Family

ID=71840842

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108399PA SG11202108399PA (en) 2019-02-02 2020-02-03 Indolo heptamyl oxime analogue as parp inhibitor

Country Status (11)

Country Link
US (1) US20220144850A1 (zh)
EP (1) EP3919495A4 (zh)
JP (1) JP2022519268A (zh)
KR (1) KR20210125024A (zh)
CN (2) CN113365998B (zh)
AU (1) AU2020214351A1 (zh)
BR (1) BR112021015149A2 (zh)
CA (1) CA3128435A1 (zh)
IL (1) IL285223A (zh)
SG (1) SG11202108399PA (zh)
WO (1) WO2020156577A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189458A1 (en) * 2020-07-31 2022-02-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indolo heptamyl oxime analog crystal as parp inhibitor and method for preparing same
CN113461597B (zh) * 2021-08-02 2023-07-21 天津太平洋化学制药有限公司 一种尼拉帕尼中间体的制备方法
WO2023226940A1 (zh) * 2022-05-23 2023-11-30 正大天晴药业集团股份有限公司 吲哚并七元酰肟类似物的用途及其药物组合

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05006B1 (et) * 1999-01-11 2008-04-15 Agouron Pharmaceuticals, Inc. Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
AU1271201A (en) * 1999-09-28 2001-04-30 Basf Aktiengesellschaft Azepinoindole derivatives, the production and use thereof
CA2537097A1 (en) * 2003-09-04 2005-03-17 Aventis Pharmaceuticals Inc. Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp)
GB201106817D0 (en) * 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
WO2015166398A1 (en) * 2014-04-30 2015-11-05 Aurigene Discovery Technologies Limited 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors

Also Published As

Publication number Publication date
EP3919495A4 (en) 2022-10-19
CN116804019A (zh) 2023-09-26
CN113365998B (zh) 2023-04-14
JP2022519268A (ja) 2022-03-22
AU2020214351A1 (en) 2021-09-09
IL285223A (en) 2021-09-30
US20220144850A1 (en) 2022-05-12
EP3919495A1 (en) 2021-12-08
CN113365998A (zh) 2021-09-07
KR20210125024A (ko) 2021-10-15
WO2020156577A1 (zh) 2020-08-06
BR112021015149A2 (pt) 2021-09-28
CA3128435A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
IL288077A (en) solid state forms
GB201905265D0 (en) Inflammasome inhibition
IL285223A (en) An indole heptamyl oxime analog as a parp inhibitor
ZA202106284B (en) Rad51 inhibitors
CA188849S (en) Showerhead
IL290087A (en) inhibitory substances
SG11202110534QA (en) Cd73 inhibitors
GB201914860D0 (en) Inhibitor compounds
IL290964A (en) A 2-aminoquinazolinone derivative
IL279419A (en) CCL5 inhibitors
IL275726A (en) Hetaryl silylethynyl compounds as nitrification inhibitors
IL283112A (en) Lox inhibitors
CA188846S (en) Showerhead
GB201809295D0 (en) Lox inhibitors
EP3773577A4 (en) TRICYCLIC ASK1 INHIBITORS
GB201905328D0 (en) Inhibitor compounds
CA195860S (en) Showerhead
CA190993S (en) Showerhead
CA190568S (en) Showerhead
CA190447S (en) Showerhead
CA190450S (en) Showerhead
CA190454S (en) Showerhead
CA190446S (en) Showerhead
CA190449S (en) Showerhead
CA190448S (en) Showerhead